TCRγδ+CD8αβ+ T cell in health and disease: a novel and functionally active subpopulation of T-cells enriched within the gut

M. Kadivar, J. Petersson, Vasileios Bekiaris, J. Marsal, L. Svensson

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

    60 Downloads (Pure)

    Abstract

    γδ T-cells have been implicated in the pathogenesis of immune-mediated diseases such asinflammatory bowel disease (IBD). However, a potential role of different immune cell subsets in IBD and also in the process of mucosal healing upon treatment is unknown. γδ T-cells have been divided into CD8αα+ and CD8- T-cells. By using flow cytometry and RT-PCR, we described for the first time anovel subset of human γδ T-cells expressing CD8αβ heterodimers on their surface. We found thatthese TCRγδ+CD8αβ+ T-cell subset exist in both human peripheral blood as well as in the gut, however they were differentially enriched within the gut. TCRγδ+CD8αβ+ T-cells displayed highcytotoxic activity by expressing Fas Ligand on their surface and also producing Granzyme B and Perforin. We showed that these cells can produce INFγ and TNFα but they did not show the ability toproduce IL-17 in healthy individuals. In patients with IBD, we found a decrease in the percentage ofintestinal CD8αβ+ γδ T-cells compared to healthy controls. Moreover, the percentage of TCRγδ+CD8αβ+ T-cells out of γδ T-cells showed a negative correlation with Crohn's disease activity.Three months of anti-TNFα (adalimumab) therapy increased the percentage of TCRγδ+CD8αβ+ T-cellsclose to the level of healthy controls. These results suggest that TCRγδ+CD8αβ+ T-cells might possiblyplay a role in gut inflammation and also intestinal wound healing after anti-TNFα treatment. These results are likely to have implications for the development of novel therapies to treat mucosal inflammatory diseases.
    Original languageEnglish
    JournalEuropean Journal of Immunology
    Volume46
    Issue numberSuppl. 1
    Pages (from-to)154-154
    ISSN0014-2980
    Publication statusPublished - 2016
    Event ICI 2016 International Congress of Immunology - Melbourne, Australia
    Duration: 21 Aug 201626 Aug 2016

    Conference

    Conference ICI 2016 International Congress of Immunology
    CountryAustralia
    CityMelbourne
    Period21/08/201626/08/2016

    Cite this

    @article{7278cfe87ce6440db4004a1729406003,
    title = "TCRγδ+CD8αβ+ T cell in health and disease: a novel and functionally active subpopulation of T-cells enriched within the gut",
    abstract = "γδ T-cells have been implicated in the pathogenesis of immune-mediated diseases such asinflammatory bowel disease (IBD). However, a potential role of different immune cell subsets in IBD and also in the process of mucosal healing upon treatment is unknown. γδ T-cells have been divided into CD8αα+ and CD8- T-cells. By using flow cytometry and RT-PCR, we described for the first time anovel subset of human γδ T-cells expressing CD8αβ heterodimers on their surface. We found thatthese TCRγδ+CD8αβ+ T-cell subset exist in both human peripheral blood as well as in the gut, however they were differentially enriched within the gut. TCRγδ+CD8αβ+ T-cells displayed highcytotoxic activity by expressing Fas Ligand on their surface and also producing Granzyme B and Perforin. We showed that these cells can produce INFγ and TNFα but they did not show the ability toproduce IL-17 in healthy individuals. In patients with IBD, we found a decrease in the percentage ofintestinal CD8αβ+ γδ T-cells compared to healthy controls. Moreover, the percentage of TCRγδ+CD8αβ+ T-cells out of γδ T-cells showed a negative correlation with Crohn's disease activity.Three months of anti-TNFα (adalimumab) therapy increased the percentage of TCRγδ+CD8αβ+ T-cellsclose to the level of healthy controls. These results suggest that TCRγδ+CD8αβ+ T-cells might possiblyplay a role in gut inflammation and also intestinal wound healing after anti-TNFα treatment. These results are likely to have implications for the development of novel therapies to treat mucosal inflammatory diseases.",
    author = "M. Kadivar and J. Petersson and Vasileios Bekiaris and J. Marsal and L. Svensson",
    year = "2016",
    language = "English",
    volume = "46",
    pages = "154--154",
    journal = "European Journal of Immunology",
    issn = "0014-2980",
    publisher = "Wiley - V C H Verlag GmbH & Co. KGaA",
    number = "Suppl. 1",

    }

    TCRγδ+CD8αβ+ T cell in health and disease: a novel and functionally active subpopulation of T-cells enriched within the gut. / Kadivar, M.; Petersson, J.; Bekiaris, Vasileios; Marsal, J.; Svensson, L.

    In: European Journal of Immunology, Vol. 46, No. Suppl. 1, 2016, p. 154-154.

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

    TY - ABST

    T1 - TCRγδ+CD8αβ+ T cell in health and disease: a novel and functionally active subpopulation of T-cells enriched within the gut

    AU - Kadivar, M.

    AU - Petersson, J.

    AU - Bekiaris, Vasileios

    AU - Marsal, J.

    AU - Svensson, L.

    PY - 2016

    Y1 - 2016

    N2 - γδ T-cells have been implicated in the pathogenesis of immune-mediated diseases such asinflammatory bowel disease (IBD). However, a potential role of different immune cell subsets in IBD and also in the process of mucosal healing upon treatment is unknown. γδ T-cells have been divided into CD8αα+ and CD8- T-cells. By using flow cytometry and RT-PCR, we described for the first time anovel subset of human γδ T-cells expressing CD8αβ heterodimers on their surface. We found thatthese TCRγδ+CD8αβ+ T-cell subset exist in both human peripheral blood as well as in the gut, however they were differentially enriched within the gut. TCRγδ+CD8αβ+ T-cells displayed highcytotoxic activity by expressing Fas Ligand on their surface and also producing Granzyme B and Perforin. We showed that these cells can produce INFγ and TNFα but they did not show the ability toproduce IL-17 in healthy individuals. In patients with IBD, we found a decrease in the percentage ofintestinal CD8αβ+ γδ T-cells compared to healthy controls. Moreover, the percentage of TCRγδ+CD8αβ+ T-cells out of γδ T-cells showed a negative correlation with Crohn's disease activity.Three months of anti-TNFα (adalimumab) therapy increased the percentage of TCRγδ+CD8αβ+ T-cellsclose to the level of healthy controls. These results suggest that TCRγδ+CD8αβ+ T-cells might possiblyplay a role in gut inflammation and also intestinal wound healing after anti-TNFα treatment. These results are likely to have implications for the development of novel therapies to treat mucosal inflammatory diseases.

    AB - γδ T-cells have been implicated in the pathogenesis of immune-mediated diseases such asinflammatory bowel disease (IBD). However, a potential role of different immune cell subsets in IBD and also in the process of mucosal healing upon treatment is unknown. γδ T-cells have been divided into CD8αα+ and CD8- T-cells. By using flow cytometry and RT-PCR, we described for the first time anovel subset of human γδ T-cells expressing CD8αβ heterodimers on their surface. We found thatthese TCRγδ+CD8αβ+ T-cell subset exist in both human peripheral blood as well as in the gut, however they were differentially enriched within the gut. TCRγδ+CD8αβ+ T-cells displayed highcytotoxic activity by expressing Fas Ligand on their surface and also producing Granzyme B and Perforin. We showed that these cells can produce INFγ and TNFα but they did not show the ability toproduce IL-17 in healthy individuals. In patients with IBD, we found a decrease in the percentage ofintestinal CD8αβ+ γδ T-cells compared to healthy controls. Moreover, the percentage of TCRγδ+CD8αβ+ T-cells out of γδ T-cells showed a negative correlation with Crohn's disease activity.Three months of anti-TNFα (adalimumab) therapy increased the percentage of TCRγδ+CD8αβ+ T-cellsclose to the level of healthy controls. These results suggest that TCRγδ+CD8αβ+ T-cells might possiblyplay a role in gut inflammation and also intestinal wound healing after anti-TNFα treatment. These results are likely to have implications for the development of novel therapies to treat mucosal inflammatory diseases.

    M3 - Conference abstract in journal

    VL - 46

    SP - 154

    EP - 154

    JO - European Journal of Immunology

    JF - European Journal of Immunology

    SN - 0014-2980

    IS - Suppl. 1

    ER -